(Q37702259)

22 August 2017

1 reference

title

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall (English)

1 reference

22 August 2017

0 references

0 references

0 references

1 reference

3

Henrik Zetterberg

1 reference

22 August 2017

2

Kaj Blennow

1 reference

22 August 2017

1

Niklas Mattsson

1 reference

22 August 2017

1 May 2010

1 reference

Clinical Chemistry and Laboratory Medicine

22 August 2017

1 reference

22 August 2017

48

1 reference

22 August 2017

603-607

1 reference

22 August 2017

5

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

22 August 2017

1 reference

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Drug discovery and the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Alzheimer's disease: new approaches to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Plasma Abeta in Alzheimer's disease--up or down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.131

21 January 2018

Identifiers

DOI

10.1515/CCLM.2010.131

1 reference

22 August 2017

1 reference

PubMed ID

20201744